OBJECTIVES: We sought to determine whether polymorphisms in the large-conductance calcium and voltage-dependent potassium (BK) channel beta1 subunit gene, KCNMB1, are associated with blood pressure response to verapamil SR or adverse outcomes in the GENEtic substudy of the INternational VErapamil SR/trandolapril STudy (INVEST-GENES). BACKGROUND: KCNMB1 is involved in calcium sensitivity and hypertension. The association between variability in KCNMB1 and calcium antagonist response, however, has not been assessed. METHODS: Genetic samples were collected from 5979 patients in INVEST. Blood pressure response to verapamil SR and time to achieve blood pressure control was assessed in relation to Glu65Lys and Val110Leu genotypes. The primary outcome (all cause mortality, nonfatal myocardial infarction or nonfatal stroke) was compared between genotype groups, and interaction with verapamil SR therapy was assessed. RESULTS: Systolic blood pressure response to verapamil SR did not differ by KCNMB1 genotype. Lys65 variant carriers, however, achieved blood pressure control earlier than Glu65Glu individuals [1.47 (interquartile ratio 2.77) versus 2.83 (interquartile ratio 4.17) months, P=0.01] and were less likely to require multiple drugs at the time of blood pressure control (adjusted odds ratio 0.43, 95% confidence interval 0.19-0.95). Leu110 variant carriers had a reduced risk of primary outcome (hazard ratio 0.68, 95% confidence interval 0.47-0.998). Subgroup analysis revealed this finding to be more pronounced in verapamil SR-assigned patients (hazard ratio 0.587, 95% confidence interval 0.33-1.04) compared with atenolol-assigned patients (hazard ratio 0.946, 95% confidence interval 0.56-1.59). No difference was seen in the occurrence of the primary outcome compared by codon 65 genotype. CONCLUSIONS: Our findings suggest that KCNMB1 genotype influences responsiveness to verapamil SR and risk of adverse cardiovascular outcomes.
OBJECTIVES: We sought to determine whether polymorphisms in the large-conductance calcium and voltage-dependent potassium (BK) channel beta1 subunit gene, KCNMB1, are associated with blood pressure response to verapamil SR or adverse outcomes in the GENEtic substudy of the INternational VErapamil SR/trandolapril STudy (INVEST-GENES). BACKGROUND:KCNMB1 is involved in calcium sensitivity and hypertension. The association between variability in KCNMB1 and calcium antagonist response, however, has not been assessed. METHODS: Genetic samples were collected from 5979 patients in INVEST. Blood pressure response to verapamil SR and time to achieve blood pressure control was assessed in relation to Glu65Lys and Val110Leu genotypes. The primary outcome (all cause mortality, nonfatal myocardial infarction or nonfatal stroke) was compared between genotype groups, and interaction with verapamil SR therapy was assessed. RESULTS: Systolic blood pressure response to verapamil SR did not differ by KCNMB1 genotype. Lys65 variant carriers, however, achieved blood pressure control earlier than Glu65Glu individuals [1.47 (interquartile ratio 2.77) versus 2.83 (interquartile ratio 4.17) months, P=0.01] and were less likely to require multiple drugs at the time of blood pressure control (adjusted odds ratio 0.43, 95% confidence interval 0.19-0.95). Leu110 variant carriers had a reduced risk of primary outcome (hazard ratio 0.68, 95% confidence interval 0.47-0.998). Subgroup analysis revealed this finding to be more pronounced in verapamil SR-assigned patients (hazard ratio 0.587, 95% confidence interval 0.33-1.04) compared with atenolol-assigned patients (hazard ratio 0.946, 95% confidence interval 0.56-1.59). No difference was seen in the occurrence of the primary outcome compared by codon 65 genotype. CONCLUSIONS: Our findings suggest that KCNMB1 genotype influences responsiveness to verapamil SR and risk of adverse cardiovascular outcomes.
Authors: Mariano Sentí; José M Fernández-Fernández; Marta Tomás; Esther Vázquez; Roberto Elosua; Jaume Marrugat; Miguel A Valverde Journal: Circ Res Date: 2005-11-17 Impact factor: 17.367
Authors: R Brenner; G J Peréz; A D Bonev; D M Eckman; J C Kosek; S W Wiler; A J Patterson; M T Nelson; R W Aldrich Journal: Nature Date: 2000-10-19 Impact factor: 49.962
Authors: Carl J Pepine; Peter R Kowey; Stuart Kupfer; Rainer E Kolloch; Athanase Benetos; Giuseppe Mancia; Antonio Coca; Rhonda M Cooper-DeHoff; Eileen Handberg; Efrain Gaxiola; Peter Sleight; C Richard Conti; Ann C Hewkin; Luigi Tavazzi Journal: J Am Coll Cardiol Date: 2006-01-18 Impact factor: 24.094
Authors: C J Pepine; E Handberg-Thurmond; R G Marks; M Conlon; R Cooper-DeHoff; P Volkers; P Zellig Journal: J Am Coll Cardiol Date: 1998-11 Impact factor: 24.094
Authors: Mark D Shriver; Rui Mei; Esteban J Parra; Vibhor Sonpar; Indrani Halder; Sarah A Tishkoff; Theodore G Schurr; Sergev I Zhadanov; Ludmila P Osipova; Tom D Brutsaert; Jonathan Friedlaender; Lynn B Jorde; W Scott Watkins; Michael J Bamshad; Gerardo Gutierrez; Halina Loi; Hajime Matsuzaki; Rick A Kittles; George Argyropoulos; Jose R Fernandez; Joshua M Akey; Keith W Jones Journal: Hum Genomics Date: 2005-06 Impact factor: 4.639
Authors: A Kelley-Hedgepeth; I Peter; Ke Kip; Mc Montefusco; S Kogan; D Cox; Jm Ordovas; D Levy; Se Reis; Me Mendelsohn; D Housman; Gs Huggins Journal: J Hum Hypertens Date: 2008-04-17 Impact factor: 3.012
Authors: Elvin Tyrone Price; Michael A Pacanowski; Michael A Martin; Rhonda M Cooper-DeHoff; Carl J Pepine; Issam Zineh; Julie A Johnson Journal: Pharmacogenet Genomics Date: 2011-06 Impact factor: 2.089
Authors: Maximilian T Lobmeyer; Liewei Wang; Issam Zineh; Stephen T Turner; John G Gums; Arlene B Chapman; Rhonda M Cooper-DeHoff; Amber L Beitelshees; Kent R Bailey; Eric Boerwinkle; Carl J Pepine; Julie A Johnson Journal: Pharmacogenet Genomics Date: 2011-01 Impact factor: 2.089
Authors: J A Johnson; L H Cavallari; A L Beitelshees; J P Lewis; A R Shuldiner; D M Roden Journal: Clin Pharmacol Ther Date: 2011-09-14 Impact factor: 6.875
Authors: Alyson Kelley-Hedgepeth; Inga Peter; Maria Claudia Montefusco; Daniel Levy; Emelia J Benjamin; Ramachandran S Vasan; Michael E Mendelsohn; David Housman; Gordon S Huggins; Gary F Mitchell Journal: J Hypertens Date: 2009-01 Impact factor: 4.844